SOLANA BEACH, Calif., June 8 /PRNewswire-FirstCall/ -- Bridgetech Holdings International, Inc. , a company focused on maximizing the potential of emerging healthcare products and services in the U.S. and Asian markets, today announced the establishment of a strategic partnership with the Mary Crowley Medical Research Center (MCMRC) for the purpose of performing clinical trials in China on investigational cancer treatment options.
Under this agreement, the Bridgetech CRO will be the exclusive provider of clinical research services to MCMRC in China. MCMRC will select certain investigational cancer treatment options and perform clinical trials on them through the Bridgetech CRO in order to facilitate obtaining regulatory approval for these treatments in China. MCMRC will also select other treatments for trials that do not yet have approval in China, to increase the number of treatment options available.
“This is another significant milestone toward achieving our long-term goal of becoming a leading developer of commercialized healthcare products and services in China,” said Michael Chermak, Chief Executive Officer of Bridgetech. “By establishing this relationship with Mary Crowley Medical Research Center we can leverage the CRO to assist in opening the door to a number of innovative vaccine, gene and cellular therapies for the treatment of cancer patients.”
“We believe that our relationships and resources in China, coupled with prestigious research facilities like the Mary Crowley Medical Research Center, can make tremendous strides in improving the treatment options available to cancer patients,” continued Mr. Chermak. “In addition, the knowledge gained in these endeavors will provide invaluable assistance to the process of making these treatments available here in the U.S.”
“We are very pleased to enter this strategic relationship with Bridgetech, said David Shanahan, President of the Mary Crowley Medical Research Center. Our main focus at MCMRC is developing safer and more effective cancer treatment options in the most efficient manner possible. We are eager to utilize the Bridgetech CRO to augment our domestic efforts in this regard. Any and all options to assist in expanding and improving the treatment options available to cancer patients need to be pursued.”
About Mary Crowley Medical Research Center
Exploring investigational vaccine, gene, and cellular therapies with the goal of expanding treatment options for all cancer patients is the primary mission of the Mary Crowley Medical Research Center. Highly trained personnel conduct early-phase studies utilizing novel therapeutic strategies in one of the most well equipped facilities in the country. The Mary Crowley Medical Research Center, located within the Baylor University Medical Center in Dallas, offers a full-service oncology clinic devoted to patient comfort and overall well-being.
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in China and the U.S. to capitalize on proprietary opportunities in high growth segments of the healthcare industry. Bridgetech is expanding its U.S. operations by adding products and services that have the highest probability for incremental success in China. In addition to the China healthcare market, Bridgetech is focusing on the areas of medical imaging and non-invasive surgery, nurse recruitment and training, and hospital asset management.
Forward-Looking Statements
Statements contained in this press release that are not statements of historical fact are “forward-looking statements” as that term is defined under federal securities laws, including, without limitation, all statements concerning expectations, beliefs, goals, intention or strategies for the future of Bridgetech. Forward-looking statements may be identified by words such as “goals,” “plans,” “believes,” “will,” “expects” and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new ventures. Many factors could cause actual events or results to differ materially from those expressed in any forward-looking statement. Investors are cautioned not to place any undue reliance on any forward-looking statements.
Investor Relations: Redwood Consultants, LLC 415-884-0348 Media: EVC Group, Inc. Steve DiMattia 917-620-0590 Approved by: Bridgetech Holdings International, Inc. Thomas C. Kuhn III 678-428-3507
Bridgetech Holdings International, Inc.
CONTACT: Investor Relations, Redwood Consultants, LLC, +1-415-884-0348,for Bridgetech Holdings International, Inc.; or Media, Steve DiMattia ofEVC Group, Inc., +1-917-620-0590, for Bridgetech Holdings International,Inc.; or Thomas C. Kuhn III of Bridgetech Holdings International, Inc.,+1-678-428-3507